Supernus Pharmaceuticals | SUPN - Cost Of Sales


Supernus Pharmaceuticals reported $59M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Abbott USD 5.94B 642M Jun/2026
ANI Pharmaceuticals USD 119.8M 5.3M Jun/2026
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Eisai JPY 51.09B 926M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Novo Nordisk DKK 17.1B 3.5B Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Perrigo USD 708.9M 65.2M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026
United Therapeutics USD 99.5M 33.9M Jun/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026